发现一种新的p38α-MK2复杂抑制剂,作为自身免疫性疾病的潜在选择
Donglin Fu1, Zimo Yang1, Xiangyu Jia1
1Chemical Pharmaceutical Research Center, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China.
Journal of medicinal chemistry
|January 9, 2025
概括
研究人员优化了CDD-450以创建化合物36,这是p38α-MK2通路的强有力的抑制剂. 这种新化合物有效地治疗炎症和关节损伤,对炎症性疾病有希望.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 在细胞炎症反应中,p38α-MK2信号通路至关重要.
- 针对这一轴为炎症性疾病提供治疗潜力.
研究的目的:
- 优化CDD-450以增强p38α-MK2抑制和改善药理动力学.
- 开发用于炎症疾病的新型治疗剂.
主要方法:
- 基于结构的药物设计和化学合成,包括"魔法F"战略.
- 分子动力学模拟以了解化化合物的结合相互作用.
- 在实验室检测细胞因子抑制 (TNF-α,IL-6) 和在实体内对老鼠和狗进行的药理动力学研究.
- 在易斯大鼠辅助剂诱导的关节炎模型中的评估.
主要成果:
- 通过"神奇F"策略获得的化合物21显示TNF-α (60倍) 和IL-6 (600倍) 抑制的显著增加.
- 分子动力学模拟提供了有关化类似物结合的见解.
- 化合物36在临床前物种中表现出改善的药物动力学特征.
- 化合物36在关节炎模型中显示出强大的抗炎作用和关节修复能力.
结论:
- 优化CDD-450导致化合物36的开发,该化合物具有增强的疗效和有利的药理动力学特性.
- 化合物36有效调节p38α-MK2通路,为炎症性疾病提供了一个有前途的治疗候选者.
- 对化合物36的进一步临床前开发是有必要的,因为它在治疗炎症病的潜在应用.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
02:26NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K